• Explore /
  • Poster
  • / Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine (Gem) in patients with pancreatic cancer (PDA).

Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine (Gem) in patients with pancreatic cancer (PDA).

Abstract Poster

Authors

null

Sunil R. Hingorani

Fred Hutchinson Cancer Research Center, Seattle, WA

Sunil R. Hingorani , William Proctor Harris , Joseph Thaddeus Beck , Boris A. Berdov , Stephanie Ann Wagner , Eduard M. Pshevlotsky , Sergei Tjulandin , Oleg Gladkov , Randall F. Holcombe , Ping Jiang , Daniel C. Maneval , Ronald I Korn , Harold Michael Shepard , Craig E. Devoe

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 300)

DOI

10.1200/jco.2015.33.3_suppl.300

Abstract #

300

Poster Bd #

B21

Abstract Disclosures

Similar Posters

Poster

2015 Gastrointestinal Cancers Symposium

Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.

Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.

First Author: Sunil R. Hingorani

First Author: Sunil R. Hingorani

First Author: Eileen Mary O'Reilly

First Author: Eileen Mary O'Reilly